Published by 
A fight that was almost a foregone conclusion: little Layla Richards, aged just 11 months and suffering from leukemia, finally emerged victorious from this ordeal.
After numerous failed treatments and when everyone thought she was doomed , the little British girl met the French biotech company Celletics.
Specializing in immunotherapy , this start-up is behind this miraculous cure . The treatment was based on CAR-T cells, molecular scissors capable of detecting and destroying tumors that evade our immune defenses.
Layla Richards is the world's first person to receive immune cell therapy to cure an aggressive form of leukemia pic.twitter.com/3kY4rwJC6j
— Good Morning Britain (@GMB) November 6, 2015
Now convinced of its effectiveness, Cellectis, the originator of real scientific progress, is now seeking to standardize these drugs and to market at affordable prices.
In fact, this type of treatment is already offered by laboratories such as Juno, Kite or Novartis but it displays prices ranging from 250 to 000 million euros per dose.
Source: Le Monde
Photo credit: BBC
